Csf 1r - Pharma

Relevant Publications

Impact of structural biology and the protein data bank on us fda new drug approvals of low molecular weight antineoplastic agents 2019-2023.

Issue Release: 2024

A novel in vitro model for investigating oligodendroglial maturation and myelin deposition under demyelinating and remyelinating conditions: Impact of microglial depletion and repopulation.

Issue Release: 2024

Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors.

Issue Release: 2024

MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients.

Issue Release: 2024

JDF promotes the apoptosis of M2 macrophages and reduces epithelial-mesenchymal transition and migration of liver cancer cells by inhibiting CSF-1/PI3K/AKT signaling pathway.

Issue Release: 2024

Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R.

Issue Release: 2024

Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study.

Issue Release: 2024

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence.

Issue Release: 2024

Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model.

Issue Release: 2024

IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis.

Issue Release: 2024

Colony stimulating factor-1 receptor drives glomerular parietal epithelial cell activation in focal segmental glomerulosclerosis.

Issue Release: 2024

Targeting the CSF-1/CSF-1R Axis: Exploring the Potential of CSF1R Inhibitors in Neurodegenerative Diseases.

Issue Release: 2024

Macrophage colony-stimulating factor and its role in the tumor microenvironment: novel therapeutic avenues and mechanistic insights.

Issue Release: 2024

Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability.

Issue Release: 2024

Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.

Issue Release: 2024

Signaling events at TMEM doorways provide potential targets for inhibiting breast cancer dissemination.

Issue Release: 2024

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.

Issue Release: 2024

[Chinese multidisciplinary expert consensus on the rational use of surufatinib in clinical practice（2024 edition）].

Issue Release: 2024

CSF-1R blockade to alleviate azithromycin mediated immunosuppression in a mouse model of intracellular infection.

Issue Release: 2024

Tricomponent immunoactivating nanomedicine to downregulate PD-L1 and polarize macrophage for photodynamic immunotherapy of colorectal cancer.

Issue Release: 2024

What are the Challenges Faced by Generic Manufacturers?

What is the Future of the Pharmacy Profession?

What is Regulatory Approval?

What are Adverse Drug Events?

How Does Cellular Stress Impact Drug Development?

Who are Pharmacists?

What Causes Adverse Drug Events?

How Can Pharma Companies Improve Patient Education?

Which Agencies are Involved?

What are the Key Cellular Stress Pathways?

Csf 1r - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics